Skip to main content

ACR 2022 Tweet by Dr. Antoni Chan

View on
Cycling to 2nd after 1st line TNFi in AxSpA provides
◦ Limited benefits to pts
◦ Few pts showed clinically meaningful improvement in disease severity after 6 months
◦ Less than 25% pts remained on therapy after 2 years
Mease P Abs1499 t.co/0Txs82KRbx #ACR22 @RheumNow
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry - ACR Meeting Abstracts
Image from Dr. Antoni Chan’s tweet
×